OncoMatch/Clinical Trials/NCT06221553
Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG
Is NCT06221553 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies B7H3 specific CAR T cell with IL-7Ra signaling domain for dipg brain tumor.
Treatment: B7H3 specific CAR T cell with IL-7Ra signaling domain — A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Intrinsic Pontine Glioma
Demographics
Prior therapy
Must have received: radiation therapy
Participants must have diffuse intrinsic pontine glioma at any timepoint following completion of standard radiotherapy
Lab requirements
Kidney function
Creatinine < 5x ULN
Liver function
AST (SGOT) < 5x ULN; ALT (SGPT) < 5x ULN; Total bilirubin < 3x ULN
Cardiac function
Presence of >= grade 3 cardiac dysfunction or symptomatic arrythmia requiring intervention [excluded]
Normal organ function: AST (SGOT) < 5x ULN; ALT (SGPT) < 5x ULN; Total bilirubin < 3x ULN; Creatinine < 5x ULN; SpO2 room air >=90%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06221553 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received radiation therapy.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages